Live Quote · NASDAQTHRDHealthcare· Biotechnology

Third Harmonic Bio, Inc.

$5.38 0.09%($-0.01)
TickerSpark Score
62/100
Mixed
95
Valuation
20
Profitability
60
Growth
84
Health
50
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a THRD research report →

52-Week Range17% of range
Low
$3.18
Current
$5.38
High
$16.02
Company Overviewwww.thirdharmonicbio.com

About the company

Third Harmonic Bio, Inc. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions for a range of allergic and inflammatory conditions. Their primary investigational compound is THB001, an orally administered small-molecule inhibitor targeting KIT.

CEO
Natalie C. Holles
IPO
2022
Employees
31
HQ
Cambridge, MA, US

Price Chart

-55.61% · this period
$15.40$9.32$3.25Aug 09Feb 11Aug 12
Valuation
Market Cap
$242.79M
P/E
4.94
P/S
0.00
P/B
0.79
EV/EBITDA
0.86
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
16.41%
ROIC
20.42%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$45.47M · 247.51%
EPS
$1.09 · 239.74%
Op Income
$58.87M
FCF YoY
-67.59%
Performance & Tape
52W High
$16.02
52W Low
$3.18
50D MA
$5.38
200D MA
$7.01
Beta
2.13
Avg Volume
262.78K

Get TickerSpark's AI analysis on THRD

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Aug 11, 25Holles Natalie C.other998,854
Aug 11, 25Holles Natalie C.other50,000
Aug 11, 25Holles Natalie C.other1,218,836
Aug 11, 25Gladstone Michaelother43,584
Aug 11, 25Murphy Christopher M.other47,500
Aug 11, 25Iwicki Mark Tother83,296
Aug 11, 25Iwicki Mark Tother128,631
Aug 11, 25Seidel Hans Martinother85,753
Aug 11, 25Seidel Hans Martinother53,090
Aug 11, 25Soloway Thomas Pother120,166
Coverage · THRD

Our THRD coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on THRD yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate THRD report →
Internal Compare

Similar companies

Peers in the same neighborhood.